Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Feb;67(2):262-3.
doi: 10.1111/j.1365-2125.2008.03315.x. Epub 2008 Dec 16.

High voriconazole trough levels in relation to hepatic function: how to adjust the dosage?

Jan-Willem C Alffenaar, Tessa de Vos, Donald R A Uges, Simon M G J Daenen

High voriconazole trough levels in relation to hepatic function: how to adjust the dosage?

Jan-Willem C Alffenaar et al. Br J Clin Pharmacol. 2009 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Voriconazole concentration over time after stopping of voriconazole. Dosage of voriconazole at time of stopping is displayed. Case 1 was a 55-year-old man with diffuse large B-cell lymphoma who received empiric stepping-up after not responding to antibacterial drugs for febrile neutropenia and recovered uneventfully. Case 2 was a 61-year-old woman with relapsed acute myeloid leukaemia (AML) who was suspected of having fungal pneumonia during a consolidation course. Case 3 was a 55-year-old woman with AML who developed febrile neutropenia and pulmonary infiltrates on X-rays and a positive galactomannan. Case 4 was a 42-year-old man who developed fungal pneumonia during aplasia, initially responding to antifungal therapy, but who succumbed later due to pulmonary bleeding. case 1 (4 mg/kg b.i.d. IV) (formula image); case 2 (4 mg/kg b.i.d. IV) (formula image); case 3 (3 mg/kg b.i.d. IV) (formula image); case 4 (3 mg/kg b.i.d. IV) (formula image); uppel level (formula image); lower level (formula image)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60. - PubMed
    1. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31:540–7. - PubMed
    1. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570–2. - PMC - PubMed
    1. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563–71. - PubMed
    1. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201–11. - PubMed

MeSH terms